1. Chronic Myeloid Leukemia Challenge

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. CML Overview

5. CML Incidence and Prevalence

6. Frontline Therapy for Newly Diagnosed CML

7. TKI Use Patterns in Newly Diagnosed CML

8. Resistance Mutations in CML

9. Treatment Options by Kinase Domain Mutations

10. Summary

11. Ponatinib

12. Ponatinib as Salvage Therapy

13. Phase 2 Trial of Ponatinib in Ph-Positive Leukemia: The PACE Trial

14. Ponatinib Dosing and Toxicity Management

15. Bosutinib

16. Bosutinib

17. Bosutinib Dosing and Toxicity Management

18. Sequential TKI Therapy

19. Omacetaxine Mepesuccinate

20. Omacetaxine Mepesuccinate

21. Omacetaxine Dosing and Toxicity Management

22. Omacetaxine in CP CML After ≥2 Prior TKIs

23. Allogeneic HSCT

24. Allogeneic HSCT as Salvage Therapy

25. TKI Maintenance After Allogeneic HSCT

26. Clinical Trials

27. Phase 1 Trial of ABL001 in CML

28. Patient Support and Communication

29. Patient Counseling: Newly Diagnosed CP CML

30. Patient Counseling: Salvage Setting